Effect of high-flux versus low-flux dialysis membranes on parathyroid hormone

Iranian Journal of Kidney Diseases

Volumn 4, Issue 4, 2010, Pages 327-332

  Makar, Samuel H ^a   Sawires, Happy K ^a   Farid, Tarek M ^b   Ali, Waleed M ^c   Schaalan, Mona F ^d  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d MISR INTERNATIONAL UNIVERSITY   (Egypt)

Author keywords

Child; Hemodiafiltration; Hemodialysis; Parathyroid hormone

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; CALCIUM; CALCIUM ION; CREATININE; ELECTROLYTE; PARATHYROID HORMONE; PHOSPHATE; POLYSULFONE; POTASSIUM; SODIUM; UREA;

ADOLESCENT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM BLOOD LEVEL; CHILD; CHILD HEALTH; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSIS MEMBRANE; ELECTROLYTE BLOOD LEVEL; EQUIPMENT DESIGN; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS; HORMONE ACTION; HORMONE TRANSPORT; HUMAN; INTERMETHOD COMPARISON; KIDNEY FAILURE; MALE; MEMBRANE FILTER; MEMBRANE PERMEABILITY; MEMBRANE TRANSPORT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRESCHOOL CHILD; SCHOOL CHILD; SODIUM BLOOD LEVEL; TREATMENT DURATION; UREA BLOOD LEVEL;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERPARATHYROIDISM; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; PARATHYROID HORMONE; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 77957360287     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Valderrabano F, Jofre R, Lopez-Gomez JM. Quality of life in end-stage renal disease patients. Am J Kidney Dis. 2001;38:443-64.
2. Unruh M, Benz R, Greene T, et al. Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. Kidney Int. 2004;66:355-66.
3. Boure T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant. 2004;19:293-6.
4. Hakim RM, Held PJ, Stannard DC, et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int. 1996;50:566-70.
5. Vanholder RC, Glorieux GL, De Smet RV. Back to the future: middle molecules, high flux membranes, and optimal dialysis. Hemodial Int. 2003;7:52-7.
6. Fischbach M, Edefonti A, Schroder C, Watson A. Hemodialysis in children: general practical guidelines. Pediatr Nephrol. 2005;20:1054-66.
7. Krieter DH, Canaud B. High permeability of dialysis membranes: what is the limit of albumin loss? Nephrol Dial Transplant. 2003;18:651-4.
8. de Francisco AL, Cobo MA, Setien MA, et al. Effect of serum phosphate on parathyroid hormone secretion during hemodialysis. Kidney Int. 1998;54:2140-5.
9. De Francisco AL, Amado JA, Prieto M, et al. Dialysis membranes and PTH changes during hemodialysis in patients with secondary hyperparathyroidism. Nephron. 1994;66:442-6.
10. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J. A bench to bedside view of uremic toxins. J Am Soc Nephrol. 2008;19:863-70.
11. Morton AR, Hercz G, Coburn JW. Control of hyperphosphatemia in chronic renal failure. Semin Dial. 1990;3:219-23.
12. Kudlac H, Fielding AM, Williams AJ. Effect of hemodialysis membrane type on parathyroid hormone removal. Miner Electrolyte Metab. 1994;20:245-9.
13. Kirschbaum B. Effect of high bicarbonate hemodialysis on ionized calcium and risk of metastatic calcification. Clin Chim Acta. 2004;343:231-6.
14. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934-43.
15. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis. 2000;35:458-64.
16. Slatopolsky E, Martin K, Hruska K. Parathyroid hormone metabolism and its potential as a uremic toxin. Am J Physiol Renal Physiol. 1980;239:F1-12.
17. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC. Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant. 2000;15:1029-34.
18. Grant FD, Conlin PR, Brown EM. Rate and concentration dependence of parathyroid hormone dynamics during stepwise changes in serum ionized calcium in normal humans. J Clin Endocrinol Metab. 1990;71:370-8.
19. Cheung AK, Levin NW, Greene T, et al. Effects of high-flux hemodialysis on clinical outcomes: results of the HEMO study. J Am Soc Nephrol. 2003;14:3251-63.
20. Silver J, Levi R. Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease. Kidney Int. 2005;67:S8-12.
21. Abbott F, Jones S, Lockwood CM, Rees AJ. Autoantibodies to glomerular antigens in patients with Wegener's granulomatosis. Nephrol Dial Transplant. 1989;4:1-8.
22. Vanholder R, Van Laecke S, Glorieux G. What is new in uremic toxicity? Pediatr Nephrol. 2008;23:1211-21.
23. Lindsay RM, Spanner E. A hypothesis: the protein catabolic rate is dependent upon the type and amount of treatment in dialyzed uremic patients. Am J Kidney Dis. 1989;13:382-9.
24. Marcus RG, Cohl E, Uribarri J. Middle molecule clearance does not influence protein intake in hemodialysis patients. Am J Kidney Dis. 1998;31:491-4.
25. Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol. 1998;9:1080-4.
26. Bergstrom J. Mechanisms of uremic suppression of appetite. J Ren Nutr. 1999;9:129-32.